309 related articles for article (PubMed ID: 22825325)
1. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
Altavilla A; Iacovelli R; Procopio G; Alesini D; Risi E; Campennì GM; Palazzo A; Cortesi E
Cancer Biol Ther; 2012 Sep; 13(11):1001-8. PubMed ID: 22825325
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
3. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
4. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):192-205. PubMed ID: 21577234
[TBL] [Abstract][Full Text] [Related]
5. New treatment options for castration-resistant prostate cancer.
Simondsen K; Kolesar J
Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
Zhong L; Pon V; Srinivas S; Nguyen N; Frear M; Kwon S; Gong C; Malmstrom R; Wilson L
PLoS One; 2013; 8(5):e64275. PubMed ID: 23717582
[TBL] [Abstract][Full Text] [Related]
7. New treatment options for castrate-resistant prostate cancer: a urology perspective.
Gomella LG; Gelpi F; Kelly WK
Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
[TBL] [Abstract][Full Text] [Related]
8. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Pal SK; Sartor O
Maturitas; 2011 Feb; 68(2):103-5. PubMed ID: 21093995
[TBL] [Abstract][Full Text] [Related]
9. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Sartor O; Michels RM; Massard C; de Bono JS
Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
[TBL] [Abstract][Full Text] [Related]
11. Castrate-resistant prostate cancer: postdocetaxel management.
Zhao S; Yu EY
Curr Opin Urol; 2013 May; 23(3):201-7. PubMed ID: 23344012
[TBL] [Abstract][Full Text] [Related]
12. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
[TBL] [Abstract][Full Text] [Related]
14. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Pal SK; Twardowski P; Sartor O
Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
[TBL] [Abstract][Full Text] [Related]
15. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging treatments in the management of castration-resistant prostate cancer.
Shapiro D; Tareen B
Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
[TBL] [Abstract][Full Text] [Related]
17. The changing therapeutic landscape of castration-resistant prostate cancer.
Yap TA; Zivi A; Omlin A; de Bono JS
Nat Rev Clin Oncol; 2011 Aug; 8(10):597-610. PubMed ID: 21826082
[TBL] [Abstract][Full Text] [Related]
18. Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials.
Iacovelli R; Altavilla A; Procopio G; Bracarda S; Santoni M; Cascinu S; Cortesi E
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):323-7. PubMed ID: 23896627
[TBL] [Abstract][Full Text] [Related]
19. [Management of metastatic castration-resistant prostate cancer following docetaxel].
Beuzeboc P; Ropert S; Goldwasser F; Zerbib M
Bull Cancer; 2012 Jul; 99 Suppl 1():S66-72. PubMed ID: 22516457
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
